We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
Trial record 3 of 8 for:    monteris

Feasibility Study on LITT for Medical Refractory Epilepsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02820740
Recruitment Status : Recruiting
First Posted : July 1, 2016
Last Update Posted : October 3, 2017
Information provided by (Responsible Party):

Study Description
Brief Summary:
Multicenter, open-label, prospective designed study to characterize the performance of brain laser interstitial thermal therapy (LITT) ablation using the Monteris NeuroBlate System for the treatment of drug-refractory medial temporal lobe epilepsy in subjects who are candidates for LITT surgery.

Condition or disease Intervention/treatment
Epilepsy Device: NeuroBlate System

Detailed Description:

Monteris is sponsoring this multicenter, open-label, prospective feasibility study to characterize the performance of laser interstitial thermal therapy (LITT) using the Monteris NeuroBlate System for the treatment of drug-refractory medial temporal lobe epilepsy in subjects who are candidates for LITT surgery.

The NeuroBlate System uses precise, high-intensity laser light to initiate necrosis of abnormal brain tissue through thermal ablation while limiting injury to healthy tissue. Unlike traditional brain surgery, LITT does not require a large opening in the skull.

Subjects who meet the study eligibility criteria and sign the informed consent form will enter a Baseline (pre-surgery) Phase to establish their baseline seizure frequency. Subjects, or their caregivers, are required to keep a seizure diary throughout the study, beginning at the first baseline visit. The study will monitor and record subjects' seizure frequency, antiepileptic medications, and physical and emotional health.

Upon demonstrating the required seizure frequency and stable antiepileptic medications for the 3-Month Baseline Phase, subjects will qualify for the study procedure. Subjects treated with NeuroBlate will have 2 years of follow-up. Throughout study participation, the study investigator will continuously monitor and document both effectiveness and safety data at study appointments.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Feasibility Study on Laser Interstitial Thermal Therapy Ablation for the Treatment of Medical Refractory Epilepsy (FLARE)
Actual Study Start Date : April 21, 2017
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Epilepsy
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
NeuroBlate LITT Treatment
This is a single arm study. All eligible study subjects will undergo LITT with the NeuroBlate System.
Device: NeuroBlate System
Laser Interstitial Thermal Therapy

Outcome Measures

Primary Outcome Measures :
  1. Adverse events [ Time Frame: 2 Years ]
    Characterize adverse events experienced in medial temporal lobe epilepsy subjects undergoing LITT using the NeuroBlate System. Adverse events will be collected based on subject reports and subject examination/testing.

  2. Changes in neuropsychological functioning [ Time Frame: 1 Year ]
    Characterize changes to neuropsychological functioning experienced in medial temporal lobe epilepsy subjects undergoing LITT using the NeuroBlate System. Descriptive statistics (via neuropsychological assessment tools) will be reported for the measured score at baseline and each follow-up visit.

Secondary Outcome Measures :
  1. Changes in seizure frequency [ Time Frame: 2 Years ]
    Characterize changes in seizure frequency experienced in medial temporal lobe epilepsy subjects undergoing LITT using the NeuroBlate System by utilizing patient diary to evaluate seizure occurrences.

  2. Surgical outcome classification [ Time Frame: 2 Years ]
    Characterize the Engel and ILAE surgical outcome classification in medial temporal lobe epilepsy subjects undergoing LITT using the NeuroBlate System. Classifications will be determined by the Investigator.

  3. Changes in quality of life [ Time Frame: 2 Years ]
    Characterize the changes in quality of life in subjects with medical temporal lobe epilepsy undergoing LITT using the NeuroBlate System. Quality of life will be measured using the QOLIE-31 questionnaire.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Relevant Inclusion Criteria are listed below

  • Diagnosis of unilateral medial temporal lobe epilepsy (MTLE) confirmed clinically and with either (1) ictal scalp recording and MRI evidence of mesial temporal sclerosis or (2) intracranial ictal onset consistent with hippocampal origin
  • Averages 3 or more complex partial seizures (with or without secondary generalization) per month
  • Refractory to antiepileptic drugs (AEDs). Subjects will be considered refractory if they have failed treatment with at least 2 AEDs due to lack of efficacy
  • Meets the criteria for a medial temporal lobe resection and is a candidate for LITT
  • 18 years or older at the time of consent

Relevant Exclusion Criteria are listed below

  • Previous diagnosis of psychogenic/non-epileptic seizures
  • Previous diagnosis of primary generalized seizures
  • IQ less than 70
  • Subject has a MRI-incompatible implanted electronic device or any metallic prosthesis or implant for which brain MRI is contraindicated
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02820740

Contact: Joan Hazen (612) 345-4544 joan@brightresearchpartners.com
Contact: Nissa Mollema (763) 253-4710 ext 2721 nmollema@monteris.com

United States, Arizona
St. Joseph's Hospital and Medical Center Recruiting
Phoenix, Arizona, United States, 85013
Contact: Arthur (Ken) Cook    602-406-6262    arthur.cook@dignityhealth.org   
Principal Investigator: Jay Varma, MD         
United States, Connecticut
Yale University School of Medicine Recruiting
New Haven, Connecticut, United States, 06520
Contact: Judith Hess    203-737-6259    judith.hess@yale.edu   
Principal Investigator: Lawrence Hirsch, MD         
Sub-Investigator: Veronica Chiang, MD         
United States, Kansas
University of Kansas Medical Center Recruiting
Kansas City, Kansas, United States, 66160
Contact: Lindsay Richardson    913-574-0412    lrichardson5@kumc.edu   
Principal Investigator: Patrick Landazuri, MD         
United States, South Carolina
Medical University of South Carolina Recruiting
Charleston, South Carolina, United States, 29425
Contact: Aparna Choudhury       choudhur@musc.edu   
Principal Investigator: Ekrem Kutluay, MD         
Sponsors and Collaborators
Monteris Medical
Principal Investigator: Dennis Spencer, MD Yale University
More Information

Responsible Party: Monteris Medical
ClinicalTrials.gov Identifier: NCT02820740     History of Changes
Other Study ID Numbers: FLARE
First Posted: July 1, 2016    Key Record Dates
Last Update Posted: October 3, 2017
Last Verified: October 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No

Keywords provided by Monteris Medical:
Medial Temporal Lobe Epilepsy
Quality of Life

Additional relevant MeSH terms:
Drug Resistant Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases